Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305734 · ClinicalTrials.gov registry record · Phase 2
Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer
A Phase 2 study of Recurrent Nasopharyngeal Cancer and Stage IV Nasopharyngeal Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00305734: Completed Phase 2 study of Recurrent Nasopharyngeal Cancer and Stage IV Nasopharyngeal Cancer, sponsored by National Cancer Institute (NCI).
NCT00305734 is a Phase 2 study of Recurrent Nasopharyngeal Cancer and Stage IV Nasopharyngeal Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00305734, a Phase 2 study of Recurrent Nasopharyngeal Cancer and Stage IV Nasopharyngeal Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well giving bortezomib together with gemcitabine works in treating patients with recurrent or metastatic nasopharyngeal cancer. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with gemcitabine may kill more tumor cells
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG bortezomib
- DRUG gemcitabine hydrochloride
Study Locations (1)
Texas
- Southwest Oncology Group - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-08 |
| Phase | Phase 2 |
What the finished NCT00305734 record still lists
NCT00305734 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Recurrent Nasopharyngeal Cancer appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00305734 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00305734 about?
NCT00305734 is a clinical study titled "Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer". This phase II trial is studying how well giving bortezomib together with gemcitabine works in treating patients with recurrent or metastatic nasopharyngeal cancer. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such a...
What is the current status of trial NCT00305734?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2006-08.
What conditions does trial NCT00305734 study?
This clinical trial studies the following conditions: Recurrent Nasopharyngeal Cancer, Stage IV Nasopharyngeal Cancer.
What interventions are being tested in trial NCT00305734?
The interventions under investigation include: laboratory biomarker analysis (OTHER), bortezomib (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00305734?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00305734 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00305734's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia